Reduced incidence of side effects by growth hormone substitution in 404 patients with pituitary insufficiency. Results of a multicenter surveillance program;Verminderte inzidenz von nebenwirkungen einer wachstumshormonsubstitution bei 404 patienten mit hypophyseninsuffizienz. Ergebnisse einer multicenteranwendungsbeobachtung

Medizinische Klinik

Volumn 93, Issue 10, 1998, Pages 585-591

  Wüster, Christian ^a,i   Melchinger, Ulrich ^b   Eversmann, Thomas ^c   Hensen, Johannes ^d   Kann, Peter ^e   Von Zur Mühlen, Alexander ^f   Ranke, Michael B ^g   Schmeil, Hannes ^b   Steinkamp, Heinz ^b   Tuschy, Ulrich ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Pharmacia and Upjohn   (Germany)

^c Praxis für Endokrinologie   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h HELIOS KLINIKUM ERFURT   (Germany)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adverse events; Cholesterol; Growth hormone; Growth hormone deficiency; IGF 1; Side effects

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CRANIOPHARYNGIOMA; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOPITUITARISM; INCIDENCE; MAJOR CLINICAL STUDY; MYALGIA; POSTMARKETING SURVEILLANCE; TITRIMETRY; VERTIGO;

PSEUDOMONAS PHAGE GH-1;

EID: 13144305040     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03042673     Document Type: Article

References (42)

1. Al Shoumer KA, Ali K, Anyaoku V, et al. Overnight metabolic fuel deficiency in patients treated conventionally for hypopituitarism. Clin Endocrinol (Oxf) 1996;45: 171-8.
2. Assmann G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) study. In: Assmann G, ed. Lipid metabolism disorders and coronary heart disease. München: MMV Medizin Verlag, 1993:19-68.
3. Bang P, Eriksson U, Sara V, et al. Comparison of acid ethanol extraction and acidgel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand, Acta Endocrinol (Copenh) 1991;124:620-9.
4. Bates AS, van Hoff W, Jones PJ, et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81;1169-72.
5. Bengtsson BÅ, Edén S, Lonn L. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76:309-17.
6. Beshyah SA, Freemantle C, Thomas E, et al. Comparison of measurements of body composition by total body potassium, bioimpedance analysis, and dual-energy X-ray absorptiometry in hypopituitary adults before and during growth hormone treatment. Am J Clin Nutr 1995;61:1186-94.
7. Beshyah SA, Freemantle C, Thomas E. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995;42:179-89.
8. Beshyah SA, Shahi M, Skinner E, et al. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur J Endocrinol 1994;130:451-8.
9. Boonen S, Aerssens J, Dequeker J. Age-related endocrine deficiencies and fractures of the proximal femur. 1. Implications of growth-hormone deficiency in the elderly. J Endocrinol 1996;149:7-12.
10. Bradly KM, Adams CB, Potter CP, et al. An audit of elected patients with non-functioning pituitary adenoma treated by transsphenoidal surgery without irradiation. Clin Endocrinol (Oxf) 1994;41:655-9.
11. Bülow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism Clin Endocrinol (Oxf) 1997;46:75-81.
12. Burman P, Broman JE, Hetta J. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995;80:3585-90.
13. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991;70: 695-700.
14. de Boer H, Blok GJ, van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrinol Rev 1995;16:63-86.
15. Doward LC. The development of the AGHDA: a measure to assess quality of life of adults with growth hormone deficiency. Quality Life Res 1995;4:420-1.
16. Fowelin J, Attvall S, Lager I, et al. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993;42:1443-7.
17. Hoffman DM, O'Sullivan AJ, Freund J, et al. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab 1995;80:72-7.
18. Holmes SJ, McKenna SP, Doward LC, et al. Development of a questionnaire to access the quality of life of adults with growth hormone deficiency. Endocrinol Metab 1995;2:63-9.
19. Holmes SJ, Shalet SM. Adult growth hormone deficiency and bone mass. Horm Res 1996;45:69-71.
20. Janssen YJH, Frölich M, Roelfsema F. A low starting dose of Genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 1997;82:129-35.
21. Johannsson G, Mårín P, Lønn L. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997;82:727-34.
22. Johannsson G, Rosén T, Lindstedt G, et al. Effect of 2 years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab 1996;3:3-12.
23. Johansson JO, Landin K, Tengborn L, et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Artenoscler Thromb 1994;14:434-7.
24. Johansson JO, Larson G, Anderson M. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995;61:57-66.
25. Jørgensen JO, Pedersen SA, Thuesen L. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221-5.
26. Jørgensen JO, Vahl N, Nyholm B. Substrate metabolism and insulin sensitivity following long-term growth hormone (GH) replacement therapy in GH-deficient adults. Endocrinol Metab 1996;3:281-6.
27. Kelly PA, Djiane J, Postel Vinay MC, et al. The prolactin/growth hormone receptor family. Endocrinol Rev 1991;2:235-51.
28. Mårdh G, Lundin K, Berg G, et al. Growth Hormone Replacement Therapy in Adult Hypopituitary Patients with Growth Hormone Deficiency: Combined Data from 12 European Placebo-Controlled Clinical Trials. Endocrinol Metabol 1994;1:Suppl A:43-9.
29. Markussis V, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituirary adults. Lancet 1992;340:1188-92.
30. Möller J, Jørgensen JO, LauersenT. Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. Clin Endocrinol (Oxf) 1993;39:403-8.
31. Nass R, Huber RM, Klauss V, et al. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995;80:552-7.
32. Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336:285-8.
33. Rosén T, Wirén L, Wilhelmsen L, et al. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 1994;40:111-6.
34. Salomon F, Cuneo RC, Hesp R, et al. The effects of treatment with recombinant human growth hormone on body composititon and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797-803.
35. Strasburger C, Kann P, Oertel H, et al. Diagnostische Kriterien für die Indikation zur Wachstumshormon-Substitution bei Erwachsenen. Dtsch Med Wochenschr 1997; 122:861-3.
36. The Principal Investigators of the MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. Wld Hlth Statist Quart 1988;41:115-40.
37. Verhelst J, Abs R, Vandeweghe M. Two years of replacement therapy in adults with growth hormone deficiency. Clin Endocrinol (Oxf) (in press).
38. Weaver JU, Monson JP, Noonan K. The eftect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995;80:153-9.
39. Wirén L, Willhelmsen L, McKenna S, et al. A comparison of the quality of life of growth hormone deficient adult and a random sample population in Sweden. 22nd Int. Sympos. on Growth Hormone and Growth Factors in Endocrinology and Metabolism, Vienna, October 1996.
40. Wüster C, Slenczka E, Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in patients with conventionally substituted pituitary insufficiency: is there a need for additional growth hormone substitution? Klin Wochenschr 1991;69:769-73.
41. Wüster C. Growth hormone, insulin-like growth factors and bone metabolism. Endocrinol Metab 1995;2:3-12.
42. Wüster C, von zur Mühlen A, Ranke M. Das Syndrom des Wachstumshormonmangels beim Erwachsenen. Dtsch érztebl 1994;91:A2402-8.